BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21849527)

  • 1. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
    Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt/beta-catenin and 3',5'-cyclic adenosine 5'-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors.
    Gaujoux S; Tissier F; Groussin L; Libé R; Ragazzon B; Launay P; Audebourg A; Dousset B; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2008 Oct; 93(10):4135-40. PubMed ID: 18647815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
    Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
    J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the expression of the oncogene YAP1, a Wnt/beta-catenin target, in adrenocortical tumors and its association with poor outcome in pediatric patients.
    Abduch RH; Carolina Bueno A; Leal LF; Cavalcanti MM; Gomes DC; Brandalise SR; Masterallo MJ; Yunes JA; Martinelli CE; Tone LG; Tucci S; Molina CA; Ramalho FS; Moreira AC; Cardinalli IA; Scrideli CA; Ramalho LN; de Castro M; Antonini SR
    Oncotarget; 2016 Dec; 7(51):84634-84644. PubMed ID: 27705928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
    Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
    Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
    Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
    Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation.
    Gaur T; Rich L; Lengner CJ; Hussain S; Trevant B; Ayers D; Stein JL; Bodine PV; Komm BS; Stein GS; Lian JB
    J Cell Physiol; 2006 Jul; 208(1):87-96. PubMed ID: 16575902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas.
    Götze S; Wolter M; Reifenberger G; Müller O; Sievers S
    Int J Cancer; 2010 Jun; 126(11):2584-93. PubMed ID: 19847810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
    Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
    J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
    Satoh S; Daigo Y; Furukawa Y; Kato T; Miwa N; Nishiwaki T; Kawasoe T; Ishiguro H; Fujita M; Tokino T; Sasaki Y; Imaoka S; Murata M; Shimano T; Yamaoka Y; Nakamura Y
    Nat Genet; 2000 Mar; 24(3):245-50. PubMed ID: 10700176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas.
    Wu R; Zhai Y; Fearon ER; Cho KR
    Cancer Res; 2001 Nov; 61(22):8247-55. PubMed ID: 11719457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.
    Thorstensen L; Lind GE; Løvig T; Diep CB; Meling GI; Rognum TO; Lothe RA
    Neoplasia; 2005 Feb; 7(2):99-108. PubMed ID: 15802015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
    Benhaj K; Akcali KC; Ozturk M
    Oncol Rep; 2006 Mar; 15(3):701-7. PubMed ID: 16465433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).
    Rogers HA; Miller S; Lowe J; Brundler MA; Coyle B; Grundy RG
    Br J Cancer; 2009 Apr; 100(8):1292-302. PubMed ID: 19293793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
    Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
    Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
    Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
    Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt signaling pathway analysis in renal cell carcinoma in young patients.
    Bruder E; Moch H; Ehrlich D; Leuschner I; Harms D; Argani P; Briner J; Graf N; Selle B; Rufle A; Paulussen M; Koesters R
    Mod Pathol; 2007 Dec; 20(12):1217-29. PubMed ID: 17873895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors.
    Kim JT; Li J; Jang ER; Gulhati P; Rychahou PG; Napier DL; Wang C; Weiss HL; Lee EY; Anthony L; Townsend CM; Liu C; Evers BM
    Carcinogenesis; 2013 May; 34(5):953-61. PubMed ID: 23354304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.